| Year |
Title |
Altmetric |
| 2023
|
Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults.
Journal of Clinical Investigation.
133.
2023
|
|
| 2023
|
Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials.
JAMA Network Open.
6:e2251974.
2023
|
|
| 2022
|
Skewed fate and hematopoiesis of CD34+ HSPCs in umbilical cord blood amid the COVID-19 pandemic.
iScience.
25.
2022
|
|
| 2022
|
Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial.
Nature Microbiology.
7:1996-2010.
2022
|
|
| 2022
|
Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens.
EBioMedicine.
84.
2022
|
|
| 2022
|
Impact of Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine.
Journal of Infectious Diseases.
226:979-982.
2022
|
|
| 2022
|
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
2022
|
|
| 2022
|
HLA-II-Associated HIV-1 Adaptation Decreases CD4+ T-Cell Responses in HIV-1 Vaccine Recipients.
Journal of Virology.
96.
2022
|
|
| 2022
|
COVID-19 Vaccination and Remdesivir are Associated With Protection From New or Increased Levels of Donor-Specific Antibodies Among Kidney Transplant Recipients Hospitalized With COVID-19.
Transplant International.
35.
2022
|
|
| 2022
|
Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody.
PLoS Pathogens.
18.
2022
|
|
| 2022
|
Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial.
Vaccine.
40:3253-3262.
2022
|
|
| 2022
|
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.
New England Journal of Medicine.
386:847-860.
2022
|
|
| 2022
|
Comprehensive mapping of SARS-CoV-2 peptide epitopes for development of a highly sensitive serological test for total and neutralizing antibodies
2022
|
|
| 2022
|
Whole-blood cytokine secretion assay as a high-throughput alternative for assessing the cell-mediated immunity profile after two doses of an adjuvanted SARS-CoV-2 recombinant protein vaccine candidate
2022
|
|
| 2021
|
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial
2021
|
|
| 2021
|
Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans.
npj Vaccines.
6.
2021
|
|
| 2021
|
Cross-Reactivity to Mutated Viral Immune Targets Can Influence CD8+ T Cell Functionality: An Alternative Viral Adaptation Strategy.
Frontiers in Immunology.
12.
2021
|
|
| 2021
|
Predictors of Nonseroconversion after SARS-CoV-2 Infection
2021
|
|
| 2021
|
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study.
Lancet Infectious Diseases.
21:1257-1270.
2021
|
|
| 2021
|
HLA-E–restricted HIV-1–specific CD8+ T cell responses in natural infection.
Journal of Clinical Investigation.
131.
2021
|
|
| 2021
|
Duration of post-COVID-19 symptoms is associated with sustained SARS-CoV-2-specific immune responses.
JCI Insight.
6.
2021
|
|
| 2021
|
Elevated HIV infection of CD4 T cells in MRKAd5 vaccine recipients due to CD8 T cells targeting adapted epitopes.
Journal of Virology.
95.
2021
|
|
| 2021
|
AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period.
Vaccine.
39:4641-4650.
2021
|
|
| 2021
|
SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence.
PLoS Pathogens.
17.
2021
|
|
| 2021
|
Safety and efficacy of single-dose Ad26.CoV2.s vaccine against covid-19.
New England Journal of Medicine.
384:2187-2201.
2021
|
|
| 2021
|
Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters.
Cell Reports Medicine.
2.
2021
|
|
| 2021
|
Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency.
Cell Reports Medicine.
2.
2021
|
|
| 2021
|
Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection.
Journal of Clinical Investigation.
131.
2021
|
|
| 2020
|
Annals on call - A primer on COVID-19 vaccines.
ACP journal club.
173.
2020
|
|
| 2020
|
Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature.
Scientific Reports.
10.
2020
|
|
| 2020
|
Remdesivir for the treatment of COVID-19 — Final report.
New England Journal of Medicine.
383:1813-1826.
2020
|
|
| 2020
|
SARS-CoV-2-specific peripheral T follicular helper cells correlate with neutralizing antibodies and increase during convalescence.
2020
|
|
| 2020
|
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.
Lancet HIV.
7:e688-e698.
2020
|
|
| 2020
|
Mechanistic inferences from clinical reports of SARS-CoV-2.
Infectious Diseases.
52:527-537.
2020
|
|
| 2020
|
Better viral control despite higher CD4+ T cell activation during acute HIV-1 infection in Zambian women is linked to the sex hormone estradiol.
Journal of Virology.
94.
2020
|
|
| 2020
|
Characterization of Type-I IFN subtype autoantibodies and activity in SLE serum and urine.
Lupus.
29:1095-1105.
2020
|
|
| 2020
|
Reply to Jakovac and to Rocha et al.: Can vitamin D prevent or manage COVID-19 illness?
2020
|
|
| 2020
|
TOX is expressed by exhausted and polyfunctional human effector memory CD8+ T cells.
Science Immunology.
5.
2020
|
|
| 2020
|
Peripheral CD4 T follicular cells induced by a conjugated pneumococcal vaccine correlate with enhanced opsonophagocytic antibody responses in younger individuals.
Vaccine.
38:1778-1786.
2020
|
|
| 2020
|
Cross-reactive CD8 T-cell responses elicited by adenovirus type 5-based HIV-1 vaccines contributed to early viral evolution in vaccine recipients who became infected.
Journal of Virology.
94.
2020
|
|
| 2019
|
Antigenic competition in CD4+ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial.
Science Translational Medicine.
11.
2019
|
|
| 2019
|
HLA-I Associated Adaptation Dampens CD8 T-Cell Responses in HIV Ad5-Vectored Vaccine Recipients.
Journal of Infectious Diseases.
220:1620-1628.
2019
|
|
| 2019
|
CD8 T cells targeting adapted epitopes in chronic HIV infection promote dendritic cell maturation and CD4 T cell trans-infection.
PLoS Pathogens.
15.
2019
|
|
| 2018
|
Antisense-derived HIV-1 cryptic epitopes are not major drivers of viral evolution during the acute phase of infection.
Journal of Virology.
92.
2018
|
|
| 2018
|
Short Communication: Apoptotic Membrane Microparticles Quantified by Fluorescent Bead-Based Assay Are Elevated in HIV and SIV Infections.
AIDS Research and Human Retroviruses.
34:446-448.
2018
|
|
| 2018
|
Immunogenetic factors in early immune control of human immunodeficiency virus type 1 (HIV-1) infection: Evaluation of HLA class I amino acid variants in two African populations.
Human Immunology.
79:166-171.
2018
|
|
| 2018
|
Progressive lentivirus infection induces natural killer cell receptor-expressing B cells in the gastrointestinal tract.
AIDS.
32:1571-1578.
2018
|
|
| 2018
|
Understanding the CD8 T-cell response in natural HIV control [version 1; referees: 3 approved].
F1000Research.
7.
2018
|
|
| 2017
|
CD151 expression is associated with a hyperproliferative T cell phenotype.
Journal of Immunology.
199:3336-3347.
2017
|
|
| 2017
|
CD4 + T cells from HIV-1 patients with impaired Th1 effector responses to Mycobacterium tuberculosis exhibit diminished histone and nucleoprotein signatures.
Clinical Immunology.
181:16-23.
2017
|
|
| 2017
|
Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults.
PLoS One.
12.
2017
|
|
| 2017
|
Dysregulation of Systemic and Mucosal Humoral Responses to Microbial and Food Antigens as a Factor Contributing to Microbial Translocation and Chronic Inflammation in HIV-1 Infection.
PLoS Pathogens.
13.
2017
|
|
| 2016
|
Balance between transmitted HLA preadapted and nonassociated polymorphisms is a major determinant of HIV-1 disease progression.
Journal of Experimental Medicine.
213:2049-2063.
2016
|
|
| 2016
|
Impact of pre-Adapted HIV transmission.
Nature Medicine.
22:606-613.
2016
|
|
| 2016
|
HIV-1-specific CD8 T cells exhibit limited cross-reactivity during acute infection.
Journal of Immunology.
196:3276-3286.
2016
|
|
| 2016
|
Enhanced allogeneic cellular responses to mismatched HLA-B antigens results in more efficient killing of HIV infected cells
2016
|
|
| 2016
|
Vaccination with heterologous HIV-1 envelope sequences and heterologous adenovirus vectors increases T-cell responses to conserved regions: HVTN 083.
Journal of Infectious Diseases.
213:541-550.
2016
|
|
| 2016
|
HIV-1 latency and virus production from unintegrated genomes following direct infection of resting CD4 T cells.
Retrovirology.
13.
2016
|
|
| 2016
|
Diminished cd103 (αeβ7) expression on resident t cells from the female genital tract of hiv-positive women.
Pathogens and Immunity.
1:371-389.
2016
|
|
| 2016
|
Dynamics and correlates of CD8 T-cell counts in Africans with primary human immunodeficiency virus type 1 infection.
Journal of Virology.
90:10423-10430.
2016
|
|
| 2016
|
Use of dried blood spots to elucidate full-length transmitted/founder hiv-1 genomes.
Pathogens and Immunity.
1:129-153.
2016
|
|
| 2015
|
Normal T-cell activation in elite controllers with preserved CD4 + T-cell counts.
AIDS.
29:2245-2254.
2015
|
|
| 2015
|
Enhanced recognition of HIV-1 cryptic epitopes restricted by HLA Class I alleles associated with a favorable clinical outcome
2015
|
|
| 2015
|
HLA Class-II Associated HIV Polymorphisms Predict Escape from CD4+ T Cell Responses.
PLoS Pathogens.
11.
2015
|
|
| 2015
|
Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals..
Journal of AIDS and Clinical Research.
6.
2015
|
|
| 2015
|
Safety and immunogenicity of modified vaccinia Ankara-Bavarian Nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virus-infected individuals: An open-label, controlled clinical phase II trial.
Open Forum Infectious Diseases.
2.
2015
|
|
| 2015
|
Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4+ T cells, and disease progression
2015
|
|
| 2015
|
Identification, molecular cloning, and analysis of full-length hepatitis C virus transmitted/founder genotypes 1, 3, and 4.
mBio.
6.
2015
|
|
| 2015
|
The HIV-1 Antisense Protein (ASP) induces CD8 T cell responses during chronic infection.
Retrovirology.
12.
2015
|
|
| 2015
|
Stable phenotypic changes of the host T cells are essential to the long-term stability of latent HIV-1 infection.
Journal of Virology.
89:6656-6672.
2015
|
|
| 2015
|
Transmitted Virus Fitness and Host T Cell Responses Collectively Define Divergent Infection Outcomes in Two HIV-1 Recipients.
PLoS Pathogens.
11:1-21.
2015
|
|
| 2014
|
Human Immunodeficiency Virus Vaccines.
Infectious Disease Clinics of North America.
28:615-631.
2014
|
|
| 2014
|
Short communication: Plasmacytoid dendritic cells from HIV-1 elite controllers maintain a gut-homing phenotype associated with immune activation.
AIDS Research and Human Retroviruses.
30:1213-1215.
2014
|
|
| 2014
|
Phase i/ii randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-Uninfected adult participants.
Clinical and Vaccine Immunology.
21:1589-1599.
2014
|
|
| 2014
|
Characterization of programmed death-1 homologue-1 (PD-1H) expression and function in normal and HIV infected individuals.
PLoS One.
9.
2014
|
|
| 2014
|
Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia ankara vaccines expressing HIV-1 virus-like particles.
Journal of Infectious Diseases.
210:99-110.
2014
|
|
| 2014
|
KIR2DS4 promotes HIV-1 pathogenesis: New evidence from analyses of immunogenetic data and natural killer cell function.
PLoS One.
9.
2014
|
|
| 2014
|
Characterization of T-Cell responses to cryptic epitopes in recipients of a noncodon-optimized HIV-1 Vaccine
2014
|
|
| 2014
|
Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients.
AIDS.
28:2627-2631.
2014
|
|
| 2014
|
Immune Suppression by Neutrophils in HIV-1 Infection: Role of PD-L1/PD-1 Pathway.
PLoS Pathogens.
10.
2014
|
|
| 2014
|
Immune activation is associated with CD8 T cell interleukin-21 production in HIV-1-infected individuals.
Journal of Virology.
88:10259-10263.
2014
|
|
| 2014
|
Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans.
Vaccine.
32:5490-5495.
2014
|
|
| 2014
|
Selection bias at the heterosexual HIV-1 transmission bottleneck.
Science.
345.
2014
|
|
| 2013
|
Dimorphic HLA-B signal peptides differentially influence HLA-E- and natural killer cell-mediated cytolysis of HIV-1-infected target cells.
Clinical and Experimental Immunology.
174:414-423.
2013
|
|
| 2013
|
HIV-specific CD8+ T cells from elite controllers are primed for survival.
Journal of Virology.
87:5170-5181.
2013
|
|
| 2013
|
Hormonal contraception and hiv-1 infection: Medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms
2013
|
|
| 2013
|
Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth.
PLoS Pathogens.
9.
2013
|
|
| 2013
|
Cumulative impact of host and viral factors on HIV-1 viral-load control during early infection.
Journal of Virology.
87:708-715.
2013
|
|
| 2012
|
Comparative evaluation of HIV-1 neutralization in external secretions and sera of HIV-1-infected women.
Open AIDS Journal.
6:293-302.
2012
|
|
| 2012
|
Role of Transmitted Gag CTL Polymorphisms in Defining Replicative Capacity and Early HIV-1 Pathogenesis.
PLoS Pathogens.
8.
2012
|
|
| 2012
|
Host factor transcriptional regulation contributes to preferential expression of HIV type 1 in IL-4-producing CD4 T cells.
Journal of Immunology.
189:2746-2757.
2012
|
|
| 2012
|
MRKAD5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load.
PLoS One.
7.
2012
|
|
| 2012
|
Elucidation of Hepatitis C Virus Transmission and Early Diversification by Single Genome Sequencing.
PLoS Pathogens.
8.
2012
|
|
| 2012
|
Corrigendum to "Modeling sequence evolution in acute HIV-1 infection" [J. Theor. Biol. 261 (2009) 341-360].
Journal of Theoretical Biology.
297:187.
2012
|
|
| 2012
|
Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in african americans.
Human Molecular Genetics.
21:4334-4347.
2012
|
|
| 2011
|
Menstrual blood as a potential source of endometrial derived CD3+ T cells.
PLoS One.
6.
2011
|
|
| 2011
|
Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated.
Journal of Experimental Medicine.
208:2237-2249.
2011
|
|
| 2011
|
Interleukin-2 production by polyfunctional HIV-1-specific CD8 T cells is associated with enhanced viral suppression
2011
|
|
| 2011
|
Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: A randomized clinical trial.
PLoS One.
6.
2011
|
|
| 2011
|
Recurrent signature patterns in hiv-1 b clade envelope glycoproteins associated with either early or chronic infections.
PLoS Pathogens.
7.
2011
|
|
| 2011
|
A phase iia randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade RAD5 HIV-1 vaccine boost in healthy adults (HVTN204).
PLoS One.
6.
2011
|
|
| 2011
|
Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women.
Journal of Infectious Diseases.
203:1534-1541.
2011
|
|
| 2011
|
CD8 T-cell proliferative capacity is compromised in primary HIV-1 infection
2011
|
|
| 2011
|
Interleukin-21-producing HIV-1-specific CD8 T cells are preferentially seen in elite controllers.
Journal of Virology.
85:2316-2324.
2011
|
|
| 2011
|
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.
Journal of Infectious Diseases.
203:610-619.
2011
|
|
| 2011
|
A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.
Vaccine.
29:1948-1958.
2011
|
|
| 2010
|
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.
Science.
330:1551-1557.
2010
|
|
| 2010
|
Profiles of human serum antibody responses elicited by three leading hiv vaccines focusing on the induction of env-specific antibodies.
PLoS One.
5.
2010
|
|
| 2010
|
Enhanced Induction of HIV-specific Cytotoxic T Lymphocytes by Dendritic Cell-targeted Delivery of SOCS-1 siRNA..
Molecular Therapy.
18:2028-2037.
2010
|
|
| 2010
|
Enhanced induction of HIV-specific cytotoxic t lymphocytes by dendritic cell-targeted delivery of SOCS-1 siRNA.
Molecular Therapy.
18:2028-2037.
2010
|
|
| 2010
|
Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1.
Virology.
396:339-348.
2010
|
|
| 2010
|
CD8 T cell response and evolutionary pressure to HIV-1 cryptic epitopes derived from antisense transcription.
Journal of Experimental Medicine.
207:51-59.
2010
|
|
| 2010
|
Perforin expression directly ex vivo by HIV-specific CD8+ T-cells is a correlate of HIV elite control.
PLoS Pathogens.
6:1-13.
2010
|
|
| 2009
|
Modeling sequence evolution in acute HIV-1 infection.
Journal of Theoretical Biology.
261:341-360.
2009
|
|
| 2009
|
OA06-03. Dynamics of CTL epitope escape and reversion in an African subtype C cohort.
Retrovirology.
6.
2009
|
|
| 2009
|
P16-04. Cryptic CTL epitopes derived from antisense transcription are frequently recognized in HIV-1 infection.
Retrovirology.
6.
2009
|
|
| 2009
|
P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting.
Retrovirology.
6.
2009
|
|
| 2009
|
S021-04 OA. A large-scale analysis of immunoglobulin sequences derived from plasmablasts/plasma cells in acute HIV-1 infection subjects.
Retrovirology.
6.
2009
|
|
| 2009
|
S03-06 OA. Rapid perforin upregulation by CD8 T cells in elite controllers as a correlate of immune-mediated control of HIV replication.
Retrovirology.
6.
2009
|
|
| 2009
|
Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection.
PLoS Medicine.
6.
2009
|
|
| 2009
|
Evolution of HLA-B 5703 hiv-1 escape mutations in HLA-B 5703-positive individuals and their transmission recipients.
Journal of Experimental Medicine.
206:909-921.
2009
|
|
| 2009
|
Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults..
AIDS Research and Human Retroviruses.
25:103-114.
2009
|
|
| 2008
|
Molecular ecology and natural history of Simian foamy virus infection in wild-living chimpanzees.
PLoS Pathogens.
4.
2008
|
|
| 2008
|
Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration.
Journal of Virology.
82:6458-6469.
2008
|
|
| 2008
|
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
2008
|
|
| 2008
|
Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients.
Journal of Experimental Medicine.
205:1009-1017.
2008
|
|
| 2008
|
Treatment response in acute/early infection versus advanced AIDS: Equivalent first and second phases of HIV RNA decline.
AIDS.
22:957-962.
2008
|
|
| 2008
|
Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B*5703-restricted gag epitope in chronic human immunodeficiency virus type 1 infection (Journal of Virology (2007) 81, 15, (8346-8351)).
Journal of Virology.
82:3161.
2008
|
|
| 2007
|
Immunological control of chronic HIV-1 infection: HLA-mediated immune function and viral evolution in adolescents.
AIDS.
21:2387-2397.
2007
|
|
| 2007
|
Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A.
Journal of Virology.
81:12608-12618.
2007
|
|
| 2007
|
Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines.
Journal of Virology.
81:12071-12076.
2007
|
|
| 2007
|
Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B*5703-restricted gag epitope in chronic human immunodeficiency virus type 1 infection.
Journal of Virology.
81:8346-8351.
2007
|
|
| 2007
|
Mutually exclusive T-cell receptor induction and differential susceptibility to human immunodeficiency virus type 1 mutational escape associated with a two-amino-acid difference between HLA class I subtypes.
Journal of Virology.
81:1619-1631.
2007
|
|
| 2007
|
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
Vaccine.
25:510-518.
2007
|
|
| 2007
|
Evaluation of cellular immune responses in subjects chronically infected with HIV type 1.
AIDS Research and Human Retroviruses.
23:67-76.
2007
|
|
| 2007
|
Functionally competent antigen-specific Cd127hi memory CD8 + T cells are preserved only in HIV-infected individuals receiving early treatment.
Journal of Infectious Diseases.
195:108-117.
2007
|
|
| 2006
|
Preterm delivery and asthma: A systematic review and meta-analysis.
Journal of Allergy and Clinical Immunology.
118:823-830.
2006
|
|
| 2006
|
Interleukin-2 reconstitutes defective human immunodeficiency virus (HIV), and cytomegalovirus (CMV) specific CD8+ T cell proliferation in HIV infection.
Journal of Medical Virology.
78:1147-1157.
2006
|
|
| 2006
|
Quantum dot semiconductor nanocrystals for immunophenotyping by polychromatic flow cytometry.
Nature Medicine.
12:972-977.
2006
|
|
| 2006
|
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells.
Blood.
107:4781-4789.
2006
|
|
| 2006
|
HIV-1 epitope-specific CD8+ T cell responses strongly associated with delayed disease progression cross-recognize epitope variants efficiently.
Journal of Immunology.
176:6130-6146.
2006
|
|
| 2006
|
Group M-based HIV-1 Gag peptides are frequently targeted by T cells in chronically infected US and Zambian patients.
AIDS.
20:353-360.
2006
|
|
| 2005
|
High-dose recombinant canarypox vaccine expressing HIV-1 protein, in seronegative human subjects.
Journal of Infectious Diseases.
192:1249-1259.
2005
|
|
| 2005
|
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.
Journal of Virology.
79:10108-10125.
2005
|
|
| 2005
|
Cutting edge: Emergence of CD127high functionally competent memory T cells is compromised by high viral loads and inadequate T cell help.
Journal of Immunology.
174:5926-5930.
2005
|
|
| 2005
|
Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection
2005
|
|
| 2005
|
Increased levels of galactose-deficient IgG in sera of HIV-1-infected individuals.
AIDS.
19:381-389.
2005
|
|
| 2005
|
Breast milk-derived antigen-specific CD8+ T cells: An extralymphoid effector memory cell population in humans.
Journal of Immunology.
174:2951-2956.
2005
|
|
| 2005
|
CD8 T-cell responses in early HIV-1 infection are skewed towards high entropy peptides.
AIDS.
19:241-250.
2005
|
|
| 2004
|
Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals.
AIDS Research and Human Retroviruses.
20:972-988.
2004
|
|
| 2004
|
Absence of immunodominant anti-gag p17 (SL9) responses among gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele.
Journal of Immunology.
173:2126-2133.
2004
|
|
| 2004
|
Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
Journal of Infectious Diseases.
189:1221-1231.
2004
|
|
| 2003
|
T Cell Responses in HIV Type 1-Infected Adolescent Minorities Share Similar Epitope Specificities with Whites Despite Significant Differences in HLA Class I Alleles.
AIDS Research and Human Retroviruses.
19:1017-1026.
2003
|
|
| 2003
|
Cross-reactive CD8+ T cell epitopes identified in US adolescent minorities
2003
|
|
| 2003
|
Antigen burden is a major determinant of human immunodeficiency virus-specific CD8+ T cell maturation state: Potential implications for therapeutic immunization.
Journal of Infectious Diseases.
187:364-374.
2003
|
|
| 2003
|
Foamy virus envelope glycoprotein is sufficient for particle budding and release.
Journal of Virology.
77:2338-2348.
2003
|
|
| 2003
|
Making sense of the HIV immune response..
Topics in antiviral medicine.
11:4-8.
2003
|
|
| 2003
|
The foamy virus envelope glycoproteins.
Current Topics in Microbiology and Immunology.
277:111-129.
2003
|
|
| 2002
|
Detection of mucosal antibodies in HIV type 1-infected individuals.
AIDS Research and Human Retroviruses.
18:1291-1300.
2002
|
|
| 2002
|
Human immunodeficiency virus-specific CD8+ T cells in human breast milk.
Journal of Virology.
76:7365-7373.
2002
|
|
| 2002
|
Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS vaccine evaluation group protocol 022A
2002
|
|
| 2002
|
Magnitude of functional CD8+ T-cell responses to the Gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma.
Journal of Virology.
76:2298-2305.
2002
|
|
| 2001
|
CD8 CTL responses in vaccines: Emerging patterns of HLA restriction and epitope recognition.
Immunology Letters.
79:37-45.
2001
|
|
| 2001
|
Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines.
Journal of Virology.
75:8681-8689.
2001
|
|
| 2001
|
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans.
Vaccine.
19:2080-2091.
2001
|
|
| 2001
|
Prognosis and risk evaluation in postoperative coronary patients: The PERISCOP study: Methodology and characteristics of the included population.
Archives of Cardiovascular Diseases.
94:9-15.
2001
|
|
| 2001
|
Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 env, gag, and pro in combination with RGP120.
Journal of Infectious Diseases.
183:563-570.
2001
|
|
| 2000
|
Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report.
ACP journal club.
133.
2000
|
|
| 2000
|
Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine.
AIDS.
14:1365-1374.
2000
|
|
| 2000
|
Characterization of the R572T point mutant of a putative cleavage site in human foamy virus env.
Journal of Virology.
74:2949-2954.
2000
|
|
| 2000
|
A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon.
Journal of Virology.
74:10249-10255.
2000
|
|
| 1999
|
MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates.
AIDS Research and Human Retroviruses.
15:921-930.
1999
|
|
| 1999
|
HIV- 1(MN) recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1(MN) recombinant glycoprotein 120 vaccine.
AIDS Research and Human Retroviruses.
15:115-132.
1999
|
|
| 1999
|
An endoplasmic reticulum retrieval signal partitions human foamy virus maturation to intracytoplasmic membranes.
Journal of Virology.
73:7210-7217.
1999
|
|
| 1997
|
A sorting motif localizes the foamy virus glycoprotein to the endoplasmic reticulum.
Journal of Virology.
71:778-784.
1997
|
|
| 1996
|
Analysis of West African hunters for foamy virus infections.
AIDS Research and Human Retroviruses.
12:1725-1730.
1996
|
|
| 1995
|
Identification of an ER retrieval signal in a retroviral glycoprotein.
Cell.
82:543-544.
1995
|
|
| 1995
|
An outbreak of Burkholderia (formerly Pseudomonas) cepacia respiratory tract colonization and infection associated with nebulized albuterol therapy.
ACP journal club.
122:762-766.
1995
|
|
